| 产品描述: | SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model. |
| 靶点: |
CXCR2;CXCR1 |
| 体内研究: |
SX-517 (化合物7) (0.1 nM-0.1 mM; 60 min) 有效抑制 10 nM CXCL8 诱导的 [35S]GTPγS 结合,IC50 为 60 nM。 Sx-517 (10 μM; 60 min) 对 HEK293 细胞中 CXCR2 细胞表面表达有抑制作用。 Sx-517 (10 μM; 0-30分钟) 阻断 HEK293 细胞中 CXCR2 介导的 ERK1/2 磷酸化。 |
| 参考文献: |
1. 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. J Med Chem. 2014 Oct 23;57(20):8378-97. 2. Ti H, et al. Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). J Med Chem. 2019 Jul 11;62(13):5944-5978. |
| 保存条件: |
2-8°C, 避光, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.616 ml |
13.081 ml |
26.163 ml |
| 5 mM |
0.523 ml |
2.616 ml |
5.233 ml |
| 10 mM |
0.262 ml |
1.308 ml |
2.616 ml |
| 50 mM |
0.052 ml |
0.262 ml |
0.523 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |